Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04251052 · ClinicalTrials.gov registry record · NA
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
A NA study of Ovarian Carcinoma, sponsored by NRG Oncology.
- Recruiting
- Registry status
- NA
- Development phase
- 1,956
- Enrollment target
- 20
- Study locations
NCT04251052: Recruiting NA study of Ovarian Carcinoma, sponsored by NRG Oncology.
NCT04251052 is a NA study of Ovarian Carcinoma that is actively recruiting participants, run by NRG Oncology. The registered enrollment target is 1,956 participants, below the 3,188-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04251052, a NA study of Ovarian Carcinoma, is actively recruiting participants, sponsored by NRG Oncology.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,956 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
Primary Outcome
Will be assessed using a stratified log rank test, stratifying for age. The effects of other covariates, such as familial history of gynecologic cancer, time to crossover for bilateral salpingectomy (BLS) patients, and age at study entry, will be adjusted for in Cox proportional hazard models. Patients who crossover will be analyzed according to the initial surgery received at study enrollment as this will reflect actual practice.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Quality-of-Life Assessment
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Bilateral Salpingectomy
- PROCEDURE Bilateral Salpingectomy with Oophorectomy
Study Locations (20)
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Tower Cancer Research Foundation - Beverly Hills
- Keck Medicine of USC Buena Park - Buena Park
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- Mercy Cancer Center - Carmichael - Carmichael
- Mercy San Juan Medical Center - Carmichael
- City of Hope Comprehensive Cancer Center - Duarte
- Kaiser Permanente Dublin - Dublin
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
Arizona
- CTCA at Western Regional Medical Center - Goodyear
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,956 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2047-06-30 |
| Phase | NA |
What NCT04251052 shows while recruiting
NCT04251052 is an interventional study that assigns participants to a tested intervention. Its 1,956 participants enrollment target places it among the larger protocols in the corpus, below the 3,188-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Ovarian Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT04251052 names 20 study sites across 5 states, led by California, Alaska, Arizona.
Frequently Asked Questions
What is clinical trial NCT04251052 about?
NCT04251052 is a clinical study titled "A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer". This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpi...
What is the current status of trial NCT04251052?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,956 participants. The study started on 2020-09-01. Estimated completion is 2047-06-30.
What conditions does trial NCT04251052 study?
This clinical trial studies the following conditions: Ovarian Carcinoma.
What interventions are being tested in trial NCT04251052?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Magnetic Resonance Imaging (PROCEDURE), Bilateral Salpingectomy (PROCEDURE), Bilateral Salpingectomy with Oophorectomy (PROCEDURE).
Who is sponsoring clinical trial NCT04251052?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04251052 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04251052's enrollment target sits among peer trials
1,956 5th of 35 higher than 31 of 35 other Ovarian Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
-
Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
RECRUITING · NA
-
Access to Genetic Testing in Underserved Patients With Cancer
RECRUITING · NA
-
The Vanguard Study: Testing a New Way to Screen for Cancer
RECRUITING · NA
-
Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
RECRUITING · NA
-
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062394 · 1,980 participants · NA
Penn Medicine Healthy Heart
- NCT07321886 · 1,980 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- NCT05233150 · 1,932 participants · NA
Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI